XOMA (NASDAQ:XOMA) Releases Quarterly Earnings Results, Misses Expectations By $0.17 EPS

XOMA (NASDAQ:XOMA) released its quarterly earnings results on Monday. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17), Zacks reports. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%.

XOMA Trading Up 1.4 %

NASDAQ XOMA traded up $0.29 during mid-day trading on Monday, reaching $20.73. 20,213 shares of the stock were exchanged, compared to its average volume of 26,083. XOMA has a 1-year low of $19.92 and a 1-year high of $35.00. The business’s fifty day simple moving average is $24.85 and its 200 day simple moving average is $27.41. The stock has a market capitalization of $244.26 million, a PE ratio of -5.96 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

Analyst Ratings Changes

Several analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a research report on Monday, February 3rd. StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

Insider Buying and Selling

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.20% of the stock is owned by company insiders.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.